Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Immuneai-CMV (Phase 1): Precision Phenotyping Reveals Heterogeneous CMV–GVHD Trade-Offs Following Allogeneic HCT | Synapse
March 3, 2026
Immuneai-CMV (Phase 1): Precision Phenotyping Reveals Heterogeneous CMV–GVHD Trade-Offs Following Allogeneic HCT
EE
Eman M. Elsabbagh
Duke University
AC
Augusto Dulanto Chiang
Vanderbilt University Medical Center
MA
Mohammad K. Alexanderani
University of Pittsburgh Medical Center
Key Points
The analysis uncovers heterogeneous trade-offs between CMV infection and GVHD outcomes.
Key findings highlight variable immune responses linked to CMV in a subset of patients.
Observational analysis highlights distinct immune response patterns after allogeneic hematopoietic cell transplantation.
These insights may guide personalized treatment strategies for managing CMV risks in transplant patients.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Elsabbagh et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76039c6e9836116a2cbfc
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.800